IP Library Granted Patent US 8,703,937
Granted Patent B2
US 8,703,937 · App. 13/465,223 · Granted Apr 22, 2014

Metal complexes of tetraazamacrocycle derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,703,937
App. No.
13/465,223
Granted
Apr 22, 2014
Kind
B2
Abstract

Improved methods for synthesizing bifunctional chelates of tetraazamacrocycle derivatives and intermediates thereof are disclosed as well as novel tetraazamacrocycle derivatives and intermediates thereof.

Claims (35)

1. A compound of Formula:

wherein,

T is a metal ion selected from the group consisting of alkali metals, alkaline earth metals, and transition metals bearing (+1) or (+2) charges;

R 11 , R 22 and R 33 are independently selected from the group consisting of —CH 2 CO 2 R 5 , —CH 2 ArOR 5 , —CH 2 SR 5 , —CH 2 PO 3 H 2 , CH 2 SO 3 H, —CH 2 Ar(OR 5 ) 2 , —CH 2 Ar(OR 5 )R 6 and —CH 2 Ar(OR 5 ) 2 R 6 ;

R 44 is —CH 2 ArOR 7 , —CH(R 5 )CO 2 R 7 , —CH 2 Ar(OR 7 ) 2 , —CH 2 Ar(OR 7 )R 5 , or —CH 2 Ar(OR 7 ) 2 R 3 ;

R 5 , R 6 and R 7 are independently H, alkyl or substituted alkyl,

R 8 is selected from a group consisting of acyl, optionally substituted aryl and heteroaryl, alkoxy, hydroxy, halo, amino, nitro, thiols, disulfides, carbohydrates, vitamins, and combinations thereof;

Ar is an optionally substituted phenyl, pyrimidinyl or pyridinyl; and

Y is a counter ion selected from the group consisting of the halides, methanesulfonate, trifluoroacetate, trifluormethanesulfonate and p-toluenesulfonate.

2. The compound of claim 1 wherein R 11 , R 22 and R 33 are independently selected from the group consisting of —CH 2 CO 2 R 5 , —CH 2 ArOR 5 , —CH 2 SR 5 , —CH 2 PO 3 H 2 , CH 2 SO 3 H, —CH 2 Ar(OR 5 ) 2 , —CH 2 Ar(OR 5 )R 6 and —CH 2 Ar(OR 5 ) 2 R 6 wherein, R 5 and R 6 are independently hydrogen, alkyl or substituted alkyl, and Ar is an optionally substituted phenyl, pyrimidinyl or pyridinyl.

3. The compound of claim 2 wherein R 5 and R 6 are independently H, t-Bu, Et or Me.

4. The compound of claim 3 wherein R 11 , R 22 and R 33 are independently —CH 2 CO 2 R 5 ; and R 5 is hydrogen or alkyl.

5. The compound of claim 4 wherein each R 11 , R 22 and R 33 is —CH 2 C(O)O-t-butyl.

6. The compound of claim 1 wherein,

R 7 is hydrogen or alkyl;

R 8 is selected from a group consisting of carboxylic acids, ethers, alcohols, fluorides, aryl, amino acids, peptides, carbohydrates, vitamins, thiols, disulfides, amines, pyridines, pyrimidines, imidazoles, triazoles, and one or more in combination.

7. The compound of claim 1 wherein R 44 is —CH 2 Ar(OR 5 )NO 2 or —CH(CO 2 R 5 )(CH 2 ) 4 NH(CO 2 )CH 2 Ar.

8. The compound of claim 7 wherein R 5 is t-butyl; R 7 and R 8 are independently hydrogen or a lower (C 1-4 ) alkyl.

9. The compound of claim 1 wherein T is an alkali or alkaline earth metal.

10. The compound of claim 9 wherein T is sodium.

11. The compound of claim 1 wherein, T is sodium and Y is bromide.

12. The compound of claim 1 wherein,

T is sodium;

R 11 , R 22 and R 33 are identical, selected from the group consisting of —CH 2 CO 2 R 5 , —CH 2 ArOR 5 , —CH 2 SR 5 , —CH 2 PO 3 H 2 , CH 2 SO 3 H, —CH 2 Ar(OR 5 ) 2 , —CH 2 Ar(OR 5 )R 6 and —CH 2 Ar(OR 5 ) 2 R 6 ; and

Y is bromide.

13. The compound of claim 12 wherein R 11 , R 22 and R 33 are independently —CH 2 CO 2 R 5 ; and R 5 is hydrogen or alkyl.

14. The compound of claim 13 wherein each of R 11 , R 22 and R 33 is —CH 2 C(O)O-t-butyl.

15. The compound of claim 1 wherein R 11 , R 22 and R 33 are independently —CH 2 CO 2 R 5 ; and R 44 is —CH 2 Ar(OR 5 )NO 2 or —CH(CO 2 R 6 )—(CH 2 ) 4 NHCO 2 CH 2 Ar.

16. The compound of claim 15 , wherein Ar is phenyl, T is sodium and Y is bromide.

17. The compound of claim 1 wherein T is an alkali metal ion; R 5 is t-butyl; R 7 and R 5 are independently hydrogen or a lower (C 1-4 alkyl and Y is a halide ion.

18. The compound of claim 1 corresponding to the structure:

1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid,

10-[(2-t-butoxy-5-nitrophenyl)methyl]-tri-t-butyl ester, sodium bromide complex.

19. The compound of claim 1 corresponding to the structure:

2-{[2′,2″-(1,4,7,10-Tetraaza-cyclododecane-1,4,7-triyl)triacetic acid]-10-yl}-6-[(benzyloxycarbonyl)-amino]hexanoic acid, tetra-t-butyl este, sodium bromide complex.

Assignments (4)
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 032480, FRAME 0001 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: THERAKOS, INC.; MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0322 →
SECURITY INTEREST Recorded Mar 19, 2014
From: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS INC.; MALLINCKRODT CARIBBEAN, INC.; MALLINCKRODT US POOL LLC; MALLINCKRODT INC.; LUDLOW CORPORATION; CNS THERAPEUTICS, INC.; ENTERPRISES HOLDINGS, INC.; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS, INC; MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC; MALLINCKRODT ENTERPRISES HOLDINGS, INC.
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 032480/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2012
From: MOORE, DENNIS A.
To: MALLINCKRODT INC.
Reel/Frame 028207/0085 →
CHANGE OF LEGAL ENTITY Recorded May 15, 2012
From: MALLINCKRODT INC.
To: MALLINCKRODT LLC
Reel/Frame 028207/0250 →